

Haematologica
HAEMATOL/2018/200204
Version 3

First line therapy in chronic lymphocytic leukemia: a Swedish
nation-wide real-world study on 1053 consecutive patients treated
between 2007 and 2013

Sandra Eketorp Sylvan, Anna Asklid, Hemming Johansson, Jenny
Klintman, Jenny Bjellvi, Staffan Tolvgård, Eva Kimby, Stefan Norin,
Per-Ola Andersson, Claes Karlsson, Karin Karlsson, Birgitta Lauri,
Mattias Mattsson, Anna Bergendahl Sandstedt, Maria Strandberg,
Anders Österborg, and Lotta Hansson

Disclosures: LH has received research grant support from Gilead and Janssen-Cilag and honoraria from Abbvie. P-OA has joined the speaker's bureau of Gilead, Janssen-Cilag and Roche and has been consultant for Abbvie, Janssen-Cilag and Roche. AO has received research grant from Abbvie, Gilead, Celgene and Janssen-Cilag and honorarium from Gilead. EK has received research grant from Pfizer and honoraria from Celgene, Gilead, Janssen-Cilag and Roche. The other authors did not have any conflicts of interest to disclosure.

Contributions: S E-S, AA, LH and AO designed the study, analysed the results and wrote the draft manuscript. HJ performed the statistical analyses and wrote the statistical part of the manuscript. S E-S, AA, JK, JB and ST audited the medical files and completed the CRFs for included patients. All authors interpreted the results, reviewed and approved the manuscript.